Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics with a Overweight.

Analyst UpgradesApr 4 21:45

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics with a Buy and maintains $7 price target.

Analyst UpgradesMar 18 19:02

Spero Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/18/2024 300% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/14/2023 300% HC Wainwright & Co. → $7 Rei

BenzingaMar 18 19:01

Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating

TipRanksMar 18 18:26

Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Yahoo FinanceMar 17 21:01

Spero Therapeutics Files $300M Mixed Securities Shelf

Seeking AlphaMar 16 04:45